Company Filing History:
Years Active: 1992-1998
Title: The Innovative Contributions of Smriti U Mehta in Monoclonal Antibody Development
Introduction
Smriti U Mehta is a distinguished inventor hailing from Libertyville, IL, in the United States. With a robust portfolio of three patents, she has made significant strides in the field of immunology, particularly in tackling Hepatitis C virus through innovative monoclonal antibodies.
Latest Patents
Among her latest patents, Smriti developed monoclonal antibodies to the Hepatitis C virus that specifically bind to the C-100 protein, 33C protein, and CORE protein of the virus. The patents also detail hybridomas that produce these antibodies and methods for their application, along with assay kits designed to utilize these monoclonal antibodies effectively.
Another notable patent focuses on monoclonal antibodies that interact with the putative Hepatitis C Virus E2/NS1 proteins. This patent includes the creation of hybridoma cell lines that secrete these antibodies, methods for their use, and corresponding assay kits for detection, further underscoring her contributions to advancing diagnostic tools in viral infections.
Career Highlights
Smriti works at Abbott Laboratories Corporation, a respected company known for its commitment to developing health technologies and solutions. Her work exemplifies the innovative spirit that Abbott embodies, enabling the development of advanced therapeutic and diagnostic tools to improve patient health outcomes.
Collaborations
Throughout her career, Smriti U Mehta has collaborated with notable colleagues such as Sushil G Devare and Jill E Johnson. These partnerships not only enhance the research environment but also facilitate the cross-pollination of ideas, leading to innovative breakthroughs in their collective efforts.
Conclusion
Smriti U Mehta stands out as a prominent inventor in the realm of biomedical research, particularly through her impactful patents related to Hepatitis C virus. Her work continues to pave the way for advancements in immunological therapies and diagnostics, reflecting a deep commitment to improving public health through innovation.